The Pretransplantation Serum Cytokine Profile inAllogeneic Stem Cell Recipients Differs from Healthy Individuals, and Various Profiles are Associated with Different Risks of Posttransplantation Complications

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 2, 2012, Pages 190-199

  Reikvam, Håkon ^a,b   Mosevoll, Knut Anders ^b   Melve, Guro Kristin ^b   Günther, Clara Cecilie ^c   Sjo, Malvin ^b   Bentsen, Pål Tore ^b   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN COMPUTING CENTER   (Norway)

Author keywords

Acute leukemia; Allogeneic stem cell transplantation; Angiogenesis; Cytokines; Graft versus host disease

Indexed keywords

CD40 LIGAND; CXCL11 CHEMOKINE; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLUID RETENTION; HUMAN; LEUKEMIA REMISSION; MALE; MYELOABLATIVE CONDITIONING; PROTEIN BLOOD LEVEL; WEIGHT GAIN;

ACUTE DISEASE; ADOLESCENT; ADULT; CYTOKINES; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855600911     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.007     Document Type: Article

References (30)

1. Kersey J.H. The role of allogeneic-cell transplantation in leukemia. N Engl J Med 2010, 363:2158-2159.
2. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
3. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
4. Bruserud O., Kittang A.O. The chemokine system in experimental and clinical hematology. Curr Top Microbiol Immunol 2010, 341:3-12.
5. Bruserud O. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia 1999, 13:1175-1187.
6. Kittang A.O., Hatfield K., Sand K., Reikvam H., Bruserud O. The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 2010, 341:149-172.
7. Dimberg A. Chemokines in angiogenesis. Curr Top Microbiol Immunol 2010, 341:59-80.
8. Hatfield K., Oyan A.M., Ersvaer E., et al. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 2009, 144:53-68.
9. Hatfield K., Ryningen A., Corbascio M., Bruserud O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer 2006, 119:2313-2321.
10. Kümpers P., Koenecke C., Hecker H., et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. Blood 2008, 112:2139-2148.
11. Kornblau S.M., McCue D., Singh N., Chen W., Estrov Z., Coombes K.R. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010, 116:4251-4261.
12. Bruserud O., Ryningen A., Olsnes A.M., et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007, 92:332-341.
13. Feng X., Scheinberg P., Wu C.O., et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica 2011, 96:602-606.
14. Filipovich A.H. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:251-257.
15. Stavrum A.K., Petersen K., Jonassen I., Dysvik B. Analysis of gene-expression data using J-Express. Curr Protoc Bioinformatics 2008, Chapter 7:Unit 7 3.
16. Apelseth T.O., Hervig T., Wentzel-Larsen T., Petersen K., Reikvam H., Bruserud O. A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. Eur Cytokine Netw 2011, 22:52-62.
17. Cooke K.R., Jannin A., Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:23-32.
18. Paczesny S., Hanauer D., Sun Y., Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant 2010, 45:1-11.
19. Gale R.P., Bortin M.M., van Bekkum D.W., et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987, 67:397-406.
20. Chaidos A., Kanfer E., Apperley J.F. Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol 2007, 20:125-154.
21. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
22. Bruserud O., Ersvaer E., Olsnes A., Gjertsen B.T. Anticancer immunotherapy in combination with proapoptotic therapy. Curr Cancer Drug Targets 2008, 8:666-675.
23. Ayala F., Dewar R., Kieran M., Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009, 23:2233-2241.
24. Hatfield K.J., Hovland R., Oyan A.M., et al. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008, 22:287-293.
25. Hatfield K.J., Olsnes A.M., Gjertsen B.T., Bruserud O. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 2005, 5:229-248.
26. Kittan N.A., Hildebrandt G.C. The chemokine system: a possible therapeutic target in acute graft versus host disease. Curr Top Microbiol Immunol 2010, 341:97-120.
27. Olsnes A.M., Motorin D., Ryningen A., Zaritskey A.Y., Bruserud O. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother 2006, 55:830-840.
28. Imado T., Iwasaki T., Kataoka Y., et al. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation. Blood 2004, 104:1542-1549.
29. Kuroiwa T., Kakishita E., Hamano T., et al. Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function. J Clin Invest 2001, 107:1365-1373.
30. Melve G.K., Ersvaer E., Kittang A.O., Bruserud Ø The chemokine system in allogeneic stem cell transplantation-a possible therapeutic target?. Expert Opin Hematol 2011, 4:563-576.